NEW YORK, NY / ACCESSWIRE / April 29, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Align Technology, Inc. ("Align" or "the Company") (NASDAQ:ALGN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Align securities between April 24, 2019 and July 24, 2019, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/algn.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information. Specifically the complaint alleges that: (1) defendants emphasized the growth and performance of the Company's operations in China, the Company's most valuable market after the United States; (2) these statements included describing the "huge market opportunity" and "tremendous growth . . . in China, in particular," and characterizing the Company's increasing presence in China as "a big hit with our Chinese customers"; (3) these and other statements were materially false and misleading because they exaggerated the Company's performance in China and omitted to disclose material declines in Chinese demand for the Company's products and the deteriorating sentiment of consumers in China towards the Company's products; and (4) consequently, the price of Align common stock was artificially inflated to a high of more than $330 per share during the Class Period.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/algn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Align you have until May 1, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 587018

NEW YORK, NY / ACCESSWIRE / April 29, 2020 / In anticipation of an onslaught of COVID-19 cases, Haiti's president, Jovenel Moïse, has created an historic public-private partnership, the Commission Multisectoral de Gestation de Pandemic COVID-19, to coordinate the country's resources and response to the looming pandemic.

President Moïse selected Dr. Jean William Pape, founder of the GHESKIO network of clinics, to co-chair the commission, along with Dr. Lauré Adrien, director general of the Haitian Ministry of Public Health and Population. The commission's immediate focus is on developing diagnosis and treatment approaches that are both effective and practical, in light of Haiti's extremely limited resources.

"The work of the commission will be critical to saving as many lives as we possibly can," said Dr. Pape.

Dr. Pape has developed a world-renowned reputation as a leader in combatting infectious diseases and saving lives. In 1980, his fight against infantile diarrhea in Haiti reduced the infant mortality rate from over 40% to less than 1% in just a year. He has been instrumental in the campaign against HIV in Haiti, resulting in a decrease in prevalence from 6.2% in 1993 to 2% today. After Haiti suffered the worst cholera outbreak in modern history, Dr. Pape led his team to serve more than 100,000 cholera patients. The protocols his GHESKIO team have developed are used to combat diseases in developing countries and around the globe.

The number of COVID-19 cases in Haiti is predicted to soar, with more than 300,000 patients projected to need hospitalization by August. The country is especially vulnerable to the pandemic, since many residents live in densely populated communities where self-isolation is physically impossible. Most of those in Port-au-Prince and surrounding communities lack access to clean water and soap.

"Survival will require unprecedented levels of creativity, collaboration and commitment among all of our partners, with a rapid release of funds to fight COVID-19," said Dr. Pape.

About Us

About GHESKIO

GHESKIO, which operates a network of clinics in Port-au-Prince and throughout Haiti, is an international leader in clinical care and research for HIV, tuberculosis and other infectious diseases. Since the earliest days of the HIV epidemic, GHESKIO has been at the forefront of HIV response, implementing testing and prevention strategies and serving as the largest provider of HIV treatment in the Caribbean. GHESKIO has been a key leader in Haiti's decrease in HIV prevalence from 6.2% in 1993 to the current level of 2.0%. GHESKIO is also the Caribbean's largest provider of tuberculosis diagnosis and treatment. GHESKIO is world-renowned for its research, with more than 35 years of continuous support from the National Institutes of Health (NIH) for single-site clinical trials. GHESKIO is a member of the prestigious AIDS Clinical Trials Group (ACTG). GHESKIO researchers have published over 250 peer-reviewed publications, and GHESKIO-developed care protocols are in use in developing nations around the world.

About Haitian Global Health Alliance

The Haitian Global Health Alliance is a U.S.-based 501(c)3 organization that provides fundraising and communication support for GHESKIO.

Contacts

Scott Morgan
Work: 1 973 865 0128
scott@hgha.org

SOURCE: Haitian Global Health Alliance in support of GHESKIO

ReleaseID: 587287

TAMPA, FL / ACCESSWIRE / April 29, 2020 / Advanzeon Solutions, Inc.'s (OTC PINK:CHCR)("Advanzeon") wholly-owned subsidiary, Pharmacy Value Management Solutions, Inc. dba SleepMaster Solutions™ (collectively, the "Company"), announced today the launch of the Company's sleep apnea program with CoreChoice, a leading specialty network PPO servicing union members.

On February 26, 2020, the Company announced its agreement with CoreChoice, pursuant to which the Company's SleepMaster Solutions™ sleep apnea program (the "SMS Program") was added to CoreChoice's specialty network as its exclusive sleep apnea services provider. CoreChoice's other specialty areas include radiology, medical air transport, neurodiagnostic testing, interventional pain management and Behavioral Health and Substance Abuse Disorders.

"The SMS Program was originally scheduled for a segmented roll out by CoreChoice commencing in March of this year. However, the timing was slightly delayed by reason of the COVID-19 pandemic. The SMS Program has now been rolled out to the first segment of our population consisting of approximately 350 of our walk-in clinics, which services in excess of one million of our Members and their dependents. While this initial launch reaches a smaller segment of our population, in view of the COVID-19 pandemic, we thought it important to immediately make the SMS Program available to as many of our Members as possible. It is our plan to continue our roll out of the SMS Program to additional segments of our population as quickly as possible," stated Dr. Steven F. Gass, CoreChoice's Chief Executive Officer.

Dr. Gass went on to say, "With no prevention vaccine available, the major defense we all have against the Coronavirus is our immune system, and a key factor supportive of our immune system is our ability to get a good night's sleep. Lack of sleep unquestionably compromises our immune system, making us more vulnerable to COVID-19. Conversely, adequate sleep supports our immune system. Sleep apnea has a direct effect on our ability to get a good night's sleep. Thus, it is extremely important for us to have as many of our Members and their dependents as possible screened and tested as quickly as possible to make certain they are obtaining good, quality sleep and maintaining the integrity of their immune system. The SMS Program does just that. CoreChoice will be affirmatively encouraging all of our Members to visit our clinics and be screened and, if indicated, tested for sleep apnea at no cost to them as we join in the fight against this deadly disease."

Clark A. Marcus, the Company's Chairman and Chief Executive Officer, stated, "Our entire team has worked closely with Dr. Gass and his team in an effort to bring the SMS Program to the CoreChoice Members as quickly as possible, even more so, because of the COVID-19 outbreak.. COVID-19 attacks the body's respiratory system, and in the severe cases we all read about, it causes death. We can fight this disease, and alongside the CoreChoice team, we can help beat it!"

About Advanzeon Solutions, Inc.

Advanzeon Solutions, Inc. (OTC PINK: CHCR) through its subsidiary owns and operates the nation's most complete sleep apnea program, SleepMaster Solutions™ (the "SMS Program"). Headquartered in Tampa, Florida, the Company's SMS Program is available in all fifty states and Washington D.C. The SMS Program focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches that address both the specific needs of clients and changing healthcare industry demands. For more information, visit our website at www.sleepmastersolutions.com.

About CoreChoice, Inc.

CoreChoice, Inc. is the only specialty network for radiology, interventional pain management, and medical air transportation services, neurodiagnostic testing and Behavioral Health and Substance Use Disorder whose mission is to reduce unnecessary health care costs through a variety of functions of health insurance, delivery of care, and administration, including our noteworthy specialty network Exclusive Provider Organization (EPO) program that is customized for each client's needs. CoreChoice services the commercial group health, workers compensation, and auto liability insurance sectors. Our clients include national labor unions, cost management companies, PPO groups, third party administrators (TPA), self-insured entities, employer groups, and government organizations. More information is available at www.corechoice.net or by calling 561-756-9110.

Safe Harbor Statement

This press release contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of our business, financial condition, liquidity, results of operations, plans and objectives. In some cases, you may identify forward-looking statements by words such as "may," "should," "plan," "intend," "potential," "continue," "believe," "expect," "predict," "anticipate" and "estimate," the negative of these words or other comparable words. These statements are only predictions. One should not place undue reliance on these forward-looking statements. The forward-looking statements are qualified by their terms and/or important factors, many of which are outside the Company's control, involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made. The forward-looking statements are based on the Company's beliefs, assumptions and expectations of our future performance, taking into account information currently available to the Company. These beliefs, assumptions and expectations can change as a result of many possible events or factors, not all of which are known to the Company. Neither the Company nor any other person assumes responsibility for the accuracy or completeness of these statements. The Company will update the information in this press release only to the extent required under applicable securities laws. If a change occurs, the Company's business, financial condition, liquidity and results of operations may vary materially from those expressed in the aforementioned forward-looking statements.

Advanzeon Public Relations Contact:
Brianna Bujnowski
Crank Communications
407-830-7312
brianna@crankcommunications.com

Advanzeon Investor Relations Contact:
Philip Pulver
Communications Director
509-607-7229
ppulver@sleepmastersolutions.com
www.AdvanzeonShareholders.com

SOURCE: Advanzeon Solutions, Inc.

ReleaseID: 587526

NEW YORK, NY / ACCESSWIRE / April 29, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Tilray, Inc. (NASDAQ:TLRY)

Investors Affected : January 15, 2019 – March 2, 2020

A class action has commenced on behalf of certain shareholders in Tilray, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the purported advantages of the marketing and revenue sharing agreement with Authentic Brands Group (the "ABG Agreement")were significantly overstated; (ii) the under performance of the ABG Agreement would foreseeably have a significant impact on the Company's financial results; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/tilray-inc-loss-submission-form/?id=6247&from=1

Intelsat S.A. (NYSE:I)

Investors Affected : November 5, 2019 – November 18, 2019

A class action has commenced on behalf of certain shareholders in Intelsat SA. The complaint filed against BC Partners, its individual partners and directors of Intelsat Raymond Svider and Justice Bateman, and Silver Lake Group, L.L.C. (and its related entities) alleges that throughout the class period, defendants made false and misleading statements to the market. Specifically, the complaint alleges that Silver Lake and its fellow defendants violated the Exchange Act by selling a block of Intelsat's shares while holding material non-public information, including the fact that the Company had met with the Federal Communications Commission (the "FCC") on November 5, 2019 to discussed the sale of spectrum controlled by Intelsat for future "5G" use (the "C-Band"). The FCC opposed Intelsat's proposal for a private sale of the C-Band, preferring a public auction. The FCC announced a public auction of the C-Band on November 18, 2019, contrary to Intelsat's wishes, its stock dropped 40%.

Shareholders may find more information at https://securitiesclasslaw.com/securities/intelsat-s-a-loss-submission-form/?id=6247&from=1

iQIYI, Inc. (NASDAQ:IQ)

Investors Affected : March 29, 2018 – April 7, 2020

A class action has commenced on behalf of certain shareholders in iQIYI, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) iQIYI inflated its revenue figures; (2) iQIYI inflated its user numbers; (3) iQIYI inflated its expenses to cover up other fraud; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/iqiyi-inc-loss-submission-form/?id=6247&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 587572

VANCOUVER, BC / ACCESSWIRE / April 29, 2020 / Lincoln Gold Mining Inc. ("Lincoln" or the "Company") (TSXV:LMG) continues unabated on its permitting efforts on its Pine Grove Gold Mine Project despite the Covid-19 pandemic. The permitting of the project in the gold rich, politically stable State of Nevada is progressing with our consultants working effectively from their home offices writing the required baseline study reports in support of the forthcoming Environmental Impact Statement (EIS). Interaction with the United States Forest Service (USFS) and the various State of Nevada agencies is taking place via teleconferencing meetings.

Paul Saxton, President of Lincoln, states "The Company believes that gold will continue to increase in price and that we are extremely pleased that our consultants have been commended by the government agencies on the fine job that they are doing in advancing the permitting for production under the present conditions."

Our lead permitting consultant, Stantec, has informed Lincoln that the botany baseline report has been approved for the Project. Our consultants are moving on to the Biological Evaluation/Biological Assessment for sensitive plant species and plan to have that submitted by May. The Air Quality Baseline Report was submitted to the USFS in early April. Specialist Reports are the immediate precursor to National Environmental Policy Act ("NEPA") and Stantec will begin drafting Specialist Reports once the baseline reports have been approved by the USFS.

About Lincoln

Lincoln Gold Mining Inc. is an advanced-stage gold mine exploration and development company holding a 100% interest in the Pine Grove Gold Project, in the Walker Lane structural zone of western Nevada. The Company has prepared a preliminary economic assessment of the Pine Grove Gold Project pursuant to National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Lincoln is working with the USFS to secure the permits necessary to develop the Pine Grove Gold Project into a low-cost heap leach operation with a high-grade gravity circuit.

Lincoln also owns an interest in a joint venture in respect of the Oro Cruz Gold Property in California. Lincoln's joint venture partner is advancing the Oro Cruz Gold Property towards further exploration, development and production.

Lincoln holds its interests in these projects through its wholly owned subsidiaries, Lincoln Resource Group Corp. and Lincoln Gold US Corporation, both Nevada corporations.

Lincoln has 20,864,596 shares issued as of April 20, 2020.

Mr. Paul Saxton, P.Eng., the Company's President and Chief Executive Officer and a "qualified person" under National Instrument 43-101, reviewed and approved the scientific and technical information in this news release.

For more information, please contact Paul Saxton, President and CEO of the Company.

On behalf of Lincoln Gold Mining Inc.

Paul Saxton
President and CEO, Lincoln Gold Mining Inc.
Tel: (604) 688-7377
Email: saxton@lincolnmining.com

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

All statements, trend analysis and other information contained in this press release relative to markets about anticipated future events or results constitute forward-looking statements. All statements, other than statements of historical fact, included herein, including, without limitation, statements relating to the price of gold, permitting process, future production of Pine Grove Gold Project, budget and timing estimates, the Company's working capital and financing opportunities and statements regarding the exploration and mineralization potential of the Company's properties, are forward-looking statements. Forward-looking statements are subject to business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those contained in the forward- looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Lincoln does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward- looking statements.

SOURCE: Lincoln Gold Mining Inc.

ReleaseID: 587499

DURHAM, NC / ACCESSWIRE / April 29, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specializing in the development of novel therapeutic and prophylactic vaccines, including one for coronavirus COVID-19 caused by SARS-CoV-2 infection, reported that it continues to advance its COVID-19 vaccine program and provided an outline of its strategy as well as anticipated Q2 2020 milestones for this program.

Heat's gp96 COVID-19 vaccine program is focused on providing prophylactic protection to elderly patients and those with underlying health conditions, the very group of patients with an increased risk of complications and death from COVID-19 infection.

New data suggest that both T-cell (cellular immunity) and antibody (humoral immunity) are required for effective prophylactic protection against COVID-19. Heat's vaccine is being designed to clear virus infected cells by promoting long-term cellular immunity, which is essential for preventing the spread of re-infection in susceptible individuals such as the elderly and other high-risk patients with relevant comorbidities.

Unlike most conventional vaccines that predominantly drive a humoral response, Heat's COVID-19 vaccine platform drives a prominent cellular immune response via CD8+ T cells, in addition to a humoral immune response via a neutralizing IgG antibody. Notably, it was observed that 30% of confirmed COVID-19 patients in China failed to develop high titers of neutralizing antibodies after COVID-19 infection, suggesting a requirement for cellular immunity for recovery. Heat's COVID-19 vaccine targets the Spike or S protein, and expresses gp96 and OX40L, a T cell co-stimulator. OX40L co-stimulation expands CD4+ helper T cells that promote B-cell differentiation and IgG/IgA antibody class switching.

Anticipated Q2 2020 milestones include:

Completion of development of a cell-based vaccine expressing gp96-Ig, OX40L-Ig and SARS-CoV-2 protein S
Generation of proof-of-concept data demonstrating vaccine immunogenicity in relevant preclinical models:

SARS-CoV-2 protein S specific CD8+ T cells in blood and lungs
SARS-CoV-2 protein S specific antibodies in serum

Submission of grant applications to fund and accelerate COVID-19 vaccine development

Jeff Wolf, Chief Executive Officer of Heat, commented, "We are making progress advancing our COVID-19 vaccine program and remain encouraged by the potential of our platform to provide broad cellular and humoral protection against COVID-19, as well as possible future mutations or other coronaviruses. Specifically, along with our University of Miami collaborators, we are finalizing completion of the vaccine and plan to commence preclinical testing this quarter. These studies will measure the antiviral immune response elicited by SARS-CoV-2 specific antigens in the context of potent immune activators, gp96 and OX40L, in both the blood and lungs of preclinical models. We expect to report our preliminary data shortly thereafter."

Mr. Wolf continued, "While we are currently funding vaccine development and preclinical studies, we do not expect to use significant corporate resources to advance our COVID-19 vaccine program. We are applying for several large grants to support clinical development of this program and are engaged in collaboration discussions, which we believe may provide attractive and non-dilutive pathways to help accelerate development of our COVID-19 vaccine."

Heat's gp96 platform has previously undergone rigorous testing in numerous National Institutes of Health (NIH) and U.S. Department of Defense (DOD)-funded mice and primate trials as a vaccine against SIV/HIV, malaria, zika and other infectious diseases. These trials have demonstrated gp96 is a powerful platform with demonstrated antiviral activity in the lungs, as evidenced by a potent immune response and effectiveness in the induction of mucosal immunity in several infectious disease models.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer and other diseases using its proprietary gp96 platform to activate CD8+ "Killer" T-cells. Heat has completed enrollment in its Phase 2 clinical trial for advanced non-small cell lung cancer with its gp96-based HS-110 therapeutic vaccine. HS-110 is the company's first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells. Heat Biologics has also launched a program in collaboration with the University of Miami to develop a vaccine designed to protect against the COVID-19 Coronavirus. Heat has numerous other pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.

Forward Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements such as Heat continuing to advance its COVID-19 vaccine program, completion of development of a cell-based vaccine expressing gp96-Ig, OX40L-Ig and SARS-CoV-2 protein S during Q2 2020, generation of proof of concept data demonstrating vaccine immunogenicity in relevant preclinical models during Q2 2020, submission of grant applications to fund and accelerate COVID-19 vaccine development during Q2 2020, the potential of the platform to provide broad cellular and humoral protection against COVID-19, as well as possible future mutations or other coronaviruses, plans to commence preclinical testing this quarter and the expected reporting of preliminary data shortly thereafter, and grant funding and collaborations providing attractive and non-dilutive pathways to help accelerate development of our COVID-19 vaccine. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat to complete the development of a cell-based vaccine expressing gp96-Ig, OX40L-Ig and SARS-CoV-2 protein S during Q2 2020, generate proof-of- concept demonstrating vaccine immunogenicity in relevant preclinical models during Q2 2020, submit grant applications to fund and accelerate COVID-19 vaccine development during Q2 2020, commence preclinical testing this quarter and report preliminary data shortly thereafter, the potential of the platform to provide broad cellular and humoral protection against COVID-19, as well as possible future mutations or other coronaviruses, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.

ReleaseID: 587527

SAN DIEGO, CA / ACCESSWIRE / April 29, 2020 / The Shareholders Foundation, Inc. announces that an investor, who purchased odd-lots of corporate bonds in the secondary market, filed a lawsuit against several big banks alleging they conspired to keep billions from small bond traders.

Investors who purchased and sold odd-lots of corporate bonds in the secondary market, you might have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The lawsuit was filed against Bank of America Securities, Inc, Barclays Capital Inc., Citigroup Inc, Credit Suisse Securities (USA) LLC, Deutsche Bank Securities Inc, The Goldman Sachs Group, Inc., JPMorgan Chase & Co., J.P. Morgan Securities LLC; Morgan Stanley, NatWest Markets Securities Inc., Wells Fargo & Co., and others.

The plaintiff claims that as a result of the defendants' conspiracy, certain investors paid more when buying, and received less when selling, their corporate bonds, suffering antitrust injury.

The plaintiff says that so-called "odd-lots" consist of any bond trade that is less than $1 million in par value, and that in 2017 and 2018, approximately 90% of corporate bond trades were less than $1 million in size,and that Corporate bond trades of less than $100,000 comprised approximately 70% of all trades.

The plaintiff claims that the defendants are market makers for both round-lots and odd-lots of corporate bonds and as such they provide both "bid" prices at which they are willing to purchase bonds and "offer" or "ask" prices at which they are willing to sell bonds, and that the difference between the bid price and the offer price is the "bid-offer spread".

The plaintiff says that by keeping the price at which Defendants buy bonds (the bid) lower than the price at which they sell bonds (the offer), Defendants capture the bid-offer spread as compensation for their market-making activities.

The plaintiff alleges that investors in the "odd-lots" persistently pay bid-offer spreads that are 25% to 300% wider than investors trading in round-lots of the same underlying bonds, and that there is evidence that supports the conclusion that the wider odd-lot bid-offer spreads paid by investors are the result of an anti-competitive, horizontal agreement among Defendants to restrict competition.

Those who purchased and sold odd-lots of corporate bonds in the secondary market, should contact the Shareholders Foundation.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 587524

Sub $22M Market Cap, Substantially Less Than 500 Employees and Limited Access to Capital Helped the Company's Eligibility Under the SBA Loan Program

The Company May Potentially Qualify for Forgiveness of a Portion of the Loan

VAN NUYS, CA / ACCESSWIRE / April 29, 2020 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world's leading clean technology manufacturer of microturbine energy systems, announced today that Capstone has applied for and received a loan under the Paycheck Protection Program (PPP) pursuant to the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The $2.6M note was entered into with its banking partner Western Alliance Bank, an Arizona corporation on April 24, 2020.

On March 24th Capstone Turbine enacted an emergency Business Continuity Plan (BCP) designed to keep employees safe and continue to support its critical aftermarket Factory Protection Plan (FPP) long-term service contracts and spare parts deliveries to its Essential Critical Infrastructure Customers, such as energy, health care, wastewater treatment, food processing services, pharmaceuticals, etc. Under the BCP, the Company furloughed, reduced hours, or reduced pay for approximately 70% of its direct workforce, leaving behind only staff deemed critical for day-to-day essential operations. In addition, Capstone Turbine's CEO and senior executive leadership voluntarily took a temporary 25% pay cut, and other managers, consisting of approximately 15% of the workforce, took a temporary 15% pay cut.

"We appreciate the federal government's commitment in supporting small businesses through the Paycheck Protection Program, along with Western Alliance Bank for their swift and efficient work to get us the appropriate funding during this unprecedented time," said Darren Jamison, President and Chief Executive Officer of Capstone Turbine. "During these times of uncertainty that the COVID-19 pandemic has created for nearly every business, having the additional liquidity provided by the PPP enhances our ability to continue manufacturing products and providing aftermarket services for our customers, which includes our global distribution network which is largely comprised of 62 small businesses, across 73 countries," added Mr. Jamison.

"A key strategic goal of the company's Business Continuity Plan in response to COVID-19 was to maintain cash flow and liquidity, and having this $2.6M PPP loan in place from the SBA in combination with the furloughs, pay cuts, and the dramatic slowing of incoming raw material are essential to keep the Company liquid and allow us to maintain our support of Capstone's essential critical infrastructure end-use customers," said Eric Hencken, Chief Financial Officer and Chief Accounting Officer of Capstone Turbine.

Capstone received the full amount of the loan on April 24, 2020, and currently plans to use the proceeds to support fixed costs such as payroll costs, rent, and utilities in accordance with the relevant terms and conditions of the CARES Act. The advance under the loan bears interest at a rate per annum of 1%. The term of the loan is two years, ending April 24, 2022. Beginning on the seventh month following the Initial disbursement date, the Company is required to pay monthly principal and interest payments, with each installment payment first to pay interest accrued since the initial disbursement date, then to bring principal current. The Company may adjust the payment amount periodically to amortize the principal over the remaining term of the note.

The loan may be forgiven partially or fully if the funding received is used for payroll costs, interest on mortgages, rent, and utilities, provided that at least 75% of the forgiven amount has been used for payroll costs. Forgiveness is based on the Company maintaining, or quickly rehiring employees and maintaining applicable salary levels. Forgiveness will be reduced if full-time headcount declines, or if salaries and wages decrease. Any forgiveness of the loan shall be subject to approval of the SBA and will require the Company and Western Alliance to apply to the SBA for such treatment in the future.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) is the world's leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, via our direct sales team, as well as our global distribution network. Capstone provides scalable solutions from 30 kWs to 10 MWs that operate on a variety of fuels and are the ideal solution for today's multi-technology distributed power generation projects.

For customers with limited capital or short-term needs, Capstone offers rental systems, for more information contact: rentals@capstoneturbine.com. To date, Capstone has shipped nearly 10,000 units to 73 countries and in FY19, saved customers an estimated $253 million in annual energy costs and 350,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, and YouTube.

Forward-Looking Statements

This press release contains "forward-looking statements," as that term is used in the federal securities laws. Forward-looking statements may be identified by words such as "expects," "believes," "objective," "intend," "targeted," "plan" and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone's filings with the Securities and Exchange Commission that may cause Capstone's actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

"Capstone" and "Capstone Microturbine" are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:

Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

Integra Investor Relations
Shawn M. Severson
415-226-7747
cpst@integra-ir.com

SOURCE: Capstone Turbine Corporation

ReleaseID: 587502

NEW YORK, NY / ACCESSWIRE / April 29, 2020 / Applied Minerals, Inc. (the "Company" or "Applied Minerals") (OTCQB:AMNL), a leading global producer of halloysite clay, under the trade name DRAGONITE, and advanced natural iron oxides, under the trade name AMIRON, announced that will dedicate additional resources toward the commercialization of silica and silicon anode material derived from halloysite clay for use in lithium-ion battery applications.

Published research has demonstrated nano-scale silica and nano-porous silicon anode material synthesized from halloysite clay significantly increases the energy storage capacity and cyclability of lithium-ion batteries. Silica and silicon-based anode material synthesized from halloysite outperforms standard silica and silicon. One objective of the battery industry is to identify a way to significantly increase the percentage of graphite (a widely used anode material) replaced by silica (~10%) and silicon (~5%) as the anode material of a lithium-ion battery. Achieving this objective would accelerate the development of the next generation of lithium-ion batteries for electrical vehicles, consumer electronics and energy grid storage.

Silica and silicon have significantly greater lithium-ion storage capacities than graphite and are the reason why battery manufacturers of electric vehicles desire to replace as much graphite as possible with silica or silicon. However, current replacement rates have been limited to 10% and 5%, respectively, because upon lithiation both standard silica and silicon experience significant volumetric expansion during charging cycles. This volumetric expansion creates stresses in the anode after the first few charging cycles, which in turn produce mechanical failures that result in a significant drop-off in battery performance.

Third-party studies have shown that, over a limited number of charging cycles, halloysite-derived silica and silicon anode material experiences a significant reduction in volumetric expansion and the associated degradation in battery performance. With additional research and development resources dedicated to building upon previous research, the Company believes the commercialization of silica and silicon anode material in lithium-ion batteries is achievable. Management is collaborating with a major global lithium-ion battery producer in the U.S., a research institute in Japan and recently began working with Brigham Young University to achieve this commercialization goal. The Company continues to work with its consultant, Greg Nielson, Ph.D., on its lithium-ion battery strategy.

The current estimated market size of graphite anode material used in electric vehicle batteries is approximately 250,000 tons per annum. This market is currently valued at $750 million – $1.0 billion. The Company believes a significant portion of this graphite anode material can eventually be replaced with halloysite-derived silica and silicon.

About Applied Minerals

Applied Minerals is the leading producer of halloysite clay and advanced natural iron oxide solutions from its wholly owned Dragon Mine property in Utah. Halloysite is aluminosilicate clay that forms naturally occurring nanotubes. In addition to serving the traditional halloysite markets for use in technical ceramics and catalytic applications, the Company has developed niche applications that benefit from the tubular morphology of its halloysite. These applications include carriers of active ingredients in paints, coatings and building materials, environmental remediation, agricultural applications and high-performance additives and fillers for plastic composites. Applied Minerals markets its halloysite products under the DRAGONITE™ trade name.

From its Dragon Mine property, the Company also produces a range of ultra-pure natural iron oxides consisting of hematite and goethite. Combining ultra-high purity and consistent quality, the inherent properties of the iron oxide from the Dragon Mine allow for a wide range of end uses in pigment and technical applications. Applied Minerals markets its comprehensive line of advanced natural iron oxide pigments under the AMIRON™ trade name. Additional information on the Company can be found at www.appliedminerals.com and www.AMIRONoxides.com.

Safe Harbor Statements

The following are safe harbor statements under the Private Securities Litigation Reform Act of 1995 for Applied Minerals, Inc. Some statements contained or implied in this news release may be considered forward-looking statements, which by their nature are uncertain. Consequently, actual results could materially differ. For more detailed information concerning how risks and uncertainties could affect the Company's revenue pipeline, please refer to Applied Minerals' most recent annual and quarterly reports filed with the SEC. The Company assumes no obligation to update any forward-looking information.

IR Contact:
Richard P. Brown
978-767-0048
rbrown@appliedminerals.com

SOURCE: Applied Minerals, Inc.

ReleaseID: 587539

SAN DIEGO, CA / ACCESSWIRE / April 29, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Becton, Dickinson and Company (NYSE:BDX).

Investors, who purchased shares of Becton, Dickinson and Company (NYSE:BDX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The plaintiff alleged that the defendants failed to disclose to investors that certain of Becton's Alaris infusion pumps experienced software errors and alarm prioritization issues, that, as a result, the Company was investing in remediation efforts to address these product issues, rather than a software upgrade to "make enhancements", that the Company was reasonably likely to face regulatory delays in connection with the software remediation, that, as a result of the foregoing, Becton was reasonably likely to recall certain of its Alaris infusion pumps, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Those who purchased Becton, Dickinson and Company (NYSE:BDX) shares should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 587505